Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  PRESCRIPTION DRUGS
A Global Strategic Business Report

This report analyzes the worldwide markets for Prescription Drugs in US$ Billion by the following therapeutic class – Oncologics/ Cancer Drugs, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents, and Others. The report provides separate comprehensive analytics for the US Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual forecasts are provided for each region for the period 2006 through 2015. A five-year historic analysis is also provided for these markets. The report profiles 292 companies including many key and niche players worldwide such as Abbott Laboratories, Allergan, Inc., Amgen, Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim Group, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Inc., Merck & Co. Inc., Merck Serono International S.A., Mylan, Inc., Novartis AG, Pfizer, Inc., Ranbaxy Laboratories Limited, Sanofi-Aventis SA, Sanofi Pasteur, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Watson Pharmaceuticals, Inc., and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1779  PAGES:    1810
PRICE:    $3950  DATE:       July 2009
COMPANIES:  292  MARKET DATA TABLES:   702
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  PRESCRIPTION DRUGS (Complete Report) Pages : 1810   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definition and Scope of Study.....I-3
  
II. EXECUTIVE SUMMARY187$2250
  1. INDUSTRY OVERVIEW & OUTLOOK.....II-112 $1200  
   Pharma Industry Hit by Economic Downturn.....II-1
Table 1: Worldwide Prescription Drugs Sales: 2006-2015 (includes corresponding Graph/Chart).....II-1
The Regional Impact.....II-1
1$300
   Emerging Markets to Drive Growth.....II-2
Biotechnology.....II-2
1$100
   Biotech Bankruptcies Rife in the Current Economic Downturn.....II-3
Economic Downturn Takes Toll on R&D.....II-3
1$100
   Outsourcing – A Mixed Bag.....II-42$200
   Generics – The Bright Spot.....II-6
Table 2: Increasing Share of Generics in the Global Pharmaceutical Market: 1995-2005 (In %) (includes corresponding Graph/Chart).....II-6
1$300
   Table 3: Generics Share in Select Markets Worldwide – United States, Germany, UK, Spain, Japan, Italy, France, Finland, Denmark, The Netherlands, Norway, and Ireland (includes corresponding Graph/Chart).....II-71$300
   Patent Expiries of Major Drugs: 2009-2012.....II-8
Patient Spending.....II-8
1$100
   Operational Restructuring.....II-9
Rising R&D Costs Call for Improved Efficiency.....II-9
Concerns Over Drug Safety and Side Effects Impede Sales.....II-9
1$100
   Policy Issues Threaten Innovation.....II-10
Regulatory Glitches and High Costs Hinder Biogeneric Growth.....II-10
1$100
   Opportunities Outside Drug Development.....II-11
Going Forward in Forward Integration.....II-11
Forward Integration into Diagnostics.....II-11
Opportunities in Healthcare.....II-11
1$100
   Down the Distribution Chain.....II-12
1$100
  2. LEADING PHARMA COMPANIES AND DRUGS WORLDWIDE.....II-133 $750  
   Pfizer Reigns Supreme .....II-13
Table 4: Leading Global Pharmaceutical Companies Worldwide by Sales (2008, 2007, and 2006) - Pfizer, GlaxoSmithKline, Novartis, Sanofi-Aventis, AstraZeneca, Roche, Johnson & Johnson, Merck & Co., Abbott and Eli Lilly - in US$ Billion (includes corresponding Graph/Chart).....II-13
1$300
   Leading Prescription Drugs Worldwide – Lipitor Leads the Way.....II-14
Table 5: Leading Prescription Drugs Worldwide by Sales (2008, 2007, and 2006)- Lipitor, Plavix, Nexium, Seretide, Enbrel, Seroquel, Zyprexa, Remicade, Singulair and Levonox in US$ Billion (includes corresponding Graph/Chart).....II-14
Oncology Tops Therapeutic Classes.....II-14
1$300
   Table 6: Leading Therapeutic Classes Worldwide by Sales (2008, 2007, and 2006)- Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others in US$ Billion (includes corresponding Graph/Chart).....II-15
1$300
  3. THERAPEUTIC DRUG CLASSES.....II-1617 $1750  
   Cholesterol Reducers.....II-16
Statins Lead the Way.....II-16
Emerging Leaders.....II-16
Table 7: Leading Cholesterol Reducing Drugs Worldwide: Sales for the years 2004 through 2008 for Lipitor, Crestor and Vytorin (in US$ Billion) (includes corresponding Graph/Chart).....II-16
1$300
   Lack of Product Differentiation Mars Prospects.....II-17
Zocor – The First Statin to Switch to OTC.....II-17
Patent Expiries of Leading Cholesterol Reducers: 2009 and Beyond.....II-17
Oncologics.....II-17
Oncologics/ Cancer Drugs – Largest Therapeutic Class.....II-17
High Unmet Needs to Drive Growth.....II-17
1$100
   Biologics to Reign Supreme.....II-18
Leading Drugs.....II-18
Leading Players.....II-18
Novel Therapies.....II-18
1$100
   Respiratory Drugs.....II-19
Leading Brands and Players.....II-19
Table 8: Leading Asthma Drugs Worldwide – Value Sales for the Years 2004-2008 for Seretide, Singulair, Symbicort and Pulmicort (in US$ Billion) (includes corresponding Graph/Chart).....II-19
1$300
   Table 9: Select COPD and Allergic Rhinitis Drugs Worldwide: Value Sales for the Years 2006-2008 for Spiriva, Nasonex and Zyrtec (In US$ Billion) (includes corresponding Graph/Chart).....II-20
Patent Expiries of Leading Respiratory Drugs: 2008 and Beyond.....II-20
Antipsychotics.....II-20
1$300
   Leading Schizophrenia Drugs.....II-21
Side Effects of Antipsychotics – A Major Issue.....II-21
Patent Expiries.....II-21
1$100
   Patent Expiries of Leading Anti-Psychotic Drugs.....II-22
Zyprexa Continues to Lose Market Share.....II-22
Risperdal Sales to Plunge, Following its Patent Expiry.....II-22
Generics - Yet to Make a Mark in Antipsychotics.....II-22
Increasing Use of Antipsychotics in Children Raises Concerns.....II-22
1$100
   Proton Pump Inhibitors.....II-231$100
   Patent Expiries of Leading Proton Pump Inhibitors: 2008 and Beyond.....II-24
Table 10: Leading Proton Pump Inhibitors Worldwide – Value Sales for the Years 2004 through 2006 (US$ Billion) - Nexium, Prevacid/Takepron, Protronix/Pantazol and AcipHex/Pariet (includes corresponding Graph/Chart).....II-24
Antidepressants.....II-24
1$300
   Patent Expiries of Leading Antidepressant Drugs Worldwide: 2005-2015.....II-25
Erythropoietins.....II-25
1$100
   Competitive Landscape in the Global Erythropoietin Market.....II-26
Leading Erythropoietin Drugs.....II-26
Table 11: Leading Erythropoietin Drugs Worldwide – Annual Revenues for the Years 2004 through 2007 in US$ Billion for Aranesp, Procrit/Eprex, Epogen and NeoRecormon (includes corresponding Graph/Chart).....II-26
1$300
   New and Pipeline Products.....II-27
Biogenerics Pose Imminent Threat.....II-27
Anti-Arthritics.....II-27
1$100
   Table 12: Leading Anti-arthritic Drugs Worldwide – Value Sales for Years 2006 through 2008 in US$ Billion - Enbrel, Remicade, Rituxan and Humira (includes corresponding Graph/Chart).....II-28
Anti-Epileptics.....II-28
1$300
   Disease Statistics.....II-29
Available Drugs.....II-29
Generics to Take the Lead in Anti-Epileptic Market.....II-29
1$100
   Table 13: Leading Anti-Epileptic Drugs Worldwide: Value Sales for years 2005 through 2007 in US$ Billion for Topamax, Lamictal, Depakote and Keppra (includes corresponding Graph/Chart).....II-30
Patent Expiries of Leading Anti-Epileptic Drugs.....II-30
New Launches.....II-30
Pipeline Drugs Bode Brighter Prospects.....II-30
1$300
   Pipeline Drugs in Antiepileptics.....II-31
Calcium Channel Blockers.....II-31
Antidiabetics.....II-31
1$100
   Table 14: Leading Anti-diabetic Drug Sales Worldwide: Value Sales for Years 2005 through 2008 in US$ Billion for Actos, Lantus, Avandia Franchise, Januivia and Byetta (includes corresponding Graph/Chart).....II-32
1$300
  4. MARKET DYNAMICS.....II-338 $800  
   Pharma M&A Activity in 2008.....II-331$100
   Aggressive M&A Deals by Japanese Companies.....II-34
Patent Expiries.....II-34
1$100
   Patent Expiries for 2008 and 2007.....II-35
New Product Approvals.....II-35
1$300
   Table 15: New Drugs Approval from 2003-2008 (includes corresponding Graph/Chart).....II-36

Table 16: Biologics Approvals from 2003-2008 (includes corresponding Graph/Chart).....II-36
1$300
   Table 17: Development of New Molecular Entities (Biological and Chemical) by Various Region/Country: Percentage Share Breakdown for the Periods 1998-2002 & 2003-2007 (includes corresponding Graph/Chart).....II-37

Table 18: Number of Compounds Under Development by Country/Region: Percentage Breakdown for the year 2007 (includes corresponding Graph/Chart).....II-37
1$300
   New Molecular Entities (NMEs) Approved by FDA in 2008.....II-38
New Biological Entities Approved by FDA in 2008.....II-38
1$100
   Research and Development.....II-39
Table 19: R&D Investments by Pharmaceutical Sector in US and Europe: 2005-2007 (includes corresponding Graph/Chart).....II-39
Cost Pressures.....II-39
R&D Productivity Slides Despite Increasing Investments.....II-39
1$300
   Aging Population Drives Demand.....II-40
Table 20: World Demographic Trends: People Over 65 as a Percentage of Total Population by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific, and Latin America for years 2000, 2008, 2010, and 2020 (includes corresponding Graph/Chart).....II-40
1$300
  5. PRESCRIPTION PHARMACEUTICALS - AN OVERVIEW.....II-415 $350  
   Biologics.....II-411$100
   Evolution Of The Global Pharmaceutical Industry.....II-421$100
   Drug Development Process – FDA Perspective.....II-43
Stages of Drug Development Process.....II-43
Drug Discovery.....II-43
Pre-Clinical Testing.....II-43
Clinical Trials.....II-43
1$100
   Phase I Clinical Trial.....II-44
Phase II Clinical Trial.....II-44
Phase III Clinical Trial.....II-44
New Drug Application.....II-44
FDA Review.....II-44
Phase IV Clinical Trials.....II-44
FDA’s Drug Safety Review – The Global Standard.....II-44
2$200
  6. SELECT THERAPEUTIC CLASSES.....II-469 $650  
   Anti-arthritics.....II-46
COX-2 Inhibitors.....II-46
Antipsychotic Drugs.....II-46
1$100
   Anti-Ulcerants.....II-47
Codeine & Combinations.....II-47
1$100
   Combination Drugs.....II-48
Anti-Depressants.....II-48
Selective Serotonin Reuptake Inhibitors (SSRIs).....II-48
1$100
   Serotonin Noradrenaline Re-Uptake Inhibitors (SNRIs).....II-49
Serotonin Modulators (5-HT2 blockers).....II-49
Dopamine-norepinephrine Reuptake Inhibitors.....II-49
1$100
   Monoamine Oxidase Inhibitors (MAOIs).....II-50
Erythropoietin.....II-50
Proton Pump Inhibitors.....II-50
1$100
   Seizure Disorder Drugs.....II-511$100
   Antihistamines.....II-521$100
   Calcium Channel Blockers.....II-531$100
   Cholesterol Reducers.....II-54
1$100
  7. MARKETING AND PROMOTIONS.....II-553 $750  
   Table 21: Promotional Spending by Major Pharma Companies (2006 and 2007) in US$ Million – Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Sanofi-Aventis, Novartis, Eli Lilly, Schering-Plough, Johnson & Johnson, and Bristol Myers Squibb (includes corresponding Graph/Chart).....II-551$300
   Table 22: Promotional Spending through Professional Detailing by Major Pharma Companies (2006 and 2007) in US$ Million – Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Novartis, Sanofi-Aventis, Eli Lilly, Johnson & Johnson, Schering-Plough and Wyeth (includes corresponding Graph/Chart).....II-56

Table 23: Direct-To-Consumer Promotional Spending By Major Pharma Companies (2006 and 2007) in US$ Million – Pfizer, GlaxoSmithKline, Merck, Bristol Myers Squibb, Sepracor, AstraZeneca, Schering-Plough, Sanofi-Aventis, Boehringer Ingelheim and Eli Lilly (includes corresponding Graph/Chart).....II-56
1$300
   Table 24: E-Promotional Spending by Major Pharma Companies (2006 and 2007) in US$ Million – Merck, GlaxoSmithKline, Johnson & Johnson, Pfizer, Shire, Eli Lilly, Schering-Plough, AstraZeneca and Sanofi- Aventis (includes corresponding Graph/Chart).....II-57
1$300
  8. RECENT INDUSTRY ACTIVITY.....II-5884 $1750  
   Merck & Co. and Schering-Plough to Merge.....II-58
Pfizer to Acquire Wyeth.....II-58
CSL and Talecris Biotherapeutics to Withdraw Merger Agreement.....II-58
AstraZeneca Partners with Merck to Analyze a New Combination of Anticancer
  Regimen.....II-58
1$100
   Sun Pharmaceutical Acquires Chattem.....II-59
Novartis Acquires 25% Stake in Alcon.....II-59
Takeda Acquires Millenium Pharmaceuticals.....II-59
1$100
   Teva Acquires Barr.....II-60
Invitrogen and Applied Biosystems Merge.....II-60
Eli Lilly Takes Over ImClone Systems.....II-60
Daiichi- Sankyo Acquires Controlling Stake in Ranbaxy.....II-60
1$100
   Fresenius Acquires APP Pharmaceuticals.....II-61
TPG Acquires 50% Stake in SIA International.....II-61
GSK Acquires Sirtris.....II-61
Shire Aquires Controlling Interest in Jerini.....II-61
Boehringer Ingelheim to Purchase Actimis Pharmaceuticals.....II-61
1$100
   Sanofi Pasteur Acquires Acambis.....II-62
Sanofi-Aventis Acquires Symbion.....II-62
Nordic and Avista Acquires ConvaTec.....II-62
King Pharmaceuticals Acquires Alpharma.....II-62
1$100
   Shionogi Acquires Sciele.....II-63
Ranbaxy Inks Indian Marketing License for GLIADEL® with BioPro.....II-63
Tibotec Gains EC Approval for PREZISTA®’s Extended Indication.....II-63
1$100
   GSK and Neptunus to Set up Joint Venture for Developing Flu Vaccines.....II-64
AstraZeneca Obtains TRO for Generic Pulmicort Respules.....II-64
Solvay Pharmaceuticals Enters Into a License Deal with Depomed.....II-64
1$100
   AstraZeneca Enters into an Agreement with Par Pharmaceutical.....II-65
BioReliance and Provecs Enter into Agreement.....II-65
Cornerstone BioPharma and Critical Therapeutics Merge to Form Cornerstone
  Therapeutics.....II-65
1$100
   GSK to Acquire Genelabs.....II-66
Lpath and Merck Serono Forge Partnership.....II-66
Allergan and Spectrum Ink Collaboration Deal for Bladder Cancer Drug.....II-66
1$100
   EMD Signs Licensing and Collaboration Deal with Theratechnologies.....II-67
Medimetriks Receives License for Prescription Brands from Perrigo.....II-67
1$100
   Forest Partners with Phenomix for Developing Diabetic Drug.....II-68
GSK Biologicals and AFFiRiS Sign Collaboration Agreement.....II-68
Sanofi-Aventis Strengthens R&D Operations in the Chinese Market.....II-68
1$100
   UCB and Pfizer Establish Cyclofluidic.....II-69
Valeant Pharmaceuticals Completes Coria Laboratories Acquisition.....II-69
1$100
   MedImmune Inks Agreement with Omninvest over Reverse Genetic Technology.....II-70
Avidas Secures North American Rights of Crown’s Dermatology Products.....II-70
1$100
   Lilly Acquires Two Compounds for Early-Stage Tuberculosis Drug Pipeline.....II-71
Eli Lilly and Deciphera Enter into Collaboration and Licensing Deal.....II-71
1$100
   Roche, GlycArt and Genentech Sign Collaboration Agreement.....II-72
Cardinal Health Plans to Spin-Off Medical and Clinical Products Businesses.....II-72
Sanofi Pasteur Holding Acquires Acambis.....II-72
1$100
   Eisai Plans NDA Submission for Insomnia Drug.....II-73
GlaxoSmithKline Enter into Strategic Alliance with Cellzome.....II-73
1$100
   Ablynx and Merck Serono Sign Nanobodies® Agreement.....II-74
GlaxoSmithKline and Valeant Enter into Collaborative Agreement.....II-74
1$100
   Noven Enters Supply and License Agreements with P&G Pharmaceuticals.....II-75
Eli Lilly Acquires SGX Pharmaceuticals.....II-75
SymBio Pharmaceuticals Enters into a License Agreement with Eisai.....II-75
1$100
   Roche Sells Four Pharmaceutical Products to Meda AB.....II-76
AstraZeneca Joins Hands with Abbott for Co-Promotion of Crestor.....II-76
1$100
   Gilead Sciences Inks Atripla®, HIV Drug Distribution Deal with Merck.....II-77
Eisai China Enters into Licensing Deal with Health Vision.....II-77
1$100
   GSK and Harvard Stem Cell Institute Team Up for Drug Discovery.....II-78
Teva Acquires Bentley Pharmaceuticals.....II-78
Roche to Acquire ARIUS Research.....II-78
1$100
   GlaxoSmithKline and Actelion Collaborate.....II-79
GSK Enters into Product Disinvestment Agreement with Aspen.....II-79
1$100
   Lupin Forges Marketing Alliance with ASCEND for Suprax® Tablets.....II-80
Merck Serono Inks Multiple Sclerosis Drug-Development Deal with Bionomics.....II-80
1$100
   European Commission Approves Kuvan® of Merck Serono.....II-81
GSK Collaborates with Mpex for Developing Anti-Bacterial Drugs.....II-81
Eli Lilly Announces Development & Licensing Agreement with TransPharma.....II-81
1$100
   Mylan Obtains Exclusive Marketing Rights for Glatiramer from NATCO.....II-82
Sepracor Acquires Oryx Pharmaceuticals.....II-82
1$100
   Mylan Takes Over Merck’s Outstanding Generics Operations.....II-83
Gilead Acquires Cicletanine Business from Navitas.....II-83
1$100
   King Pharmaceuticals to License Third Opioid Analgesic Product.....II-84
BioPhausia Acquires Prescription Pharmaceutical Offerings from AstraZeneca.....II-84
Ranbaxy Enters into Strategic Product Development Agreement with Merck.....II-84
1$100
   EUSA Pharma Acquires Cytogen Corporation.....II-85
Dr. Reddy’s Announces Two Major Acquisitions.....II-85
EUSA Divests Stake in Antibody Research and Oncology Product to IDD.....II-85
1$100
   Sanofi Pasteur Delivers H5N1 Bulk Vaccine Antigen to HHS.....II-86
Ranbaxy Inks Strategic Business Alliance with Orchid.....II-86
1$100
   Pfizer Settles Patent Litigation for Lipitor with Ranbaxy.....II-87
GSK Enters into Collaboration with Regulus Therapeutics.....II-87
1$100
   Janssen to Launch J&J Group’s New Drugs in Japan.....II-88
Roche Alliance Partner Obtains Approval for Actemra in Japan.....II-88
Abbott Receives Japanese Approval for Rheumatoid Arthritis Drug, HUMIRA®.....II-88
1$100
   Dr. Reddy’s Completes Acquisition of Jet Generici Srl.....II-89
Eli Lilly, Transition Therapeutics Announce Licensing and Partnership
  Agreement.....II-89
Dr. Reddy’s and 7TM Sign Drug Discovery Agreement for Selected Drug Targets.....II-89
1$100
   Endo Pharmaceuticals Obtains US Rights for Novartis’ Voltaren® Gel.....II-90
Pfizer to Take Over Serenex.....II-90
1$100
   Sanofi-aventis, Amyris, iOWH Sign Semisynthetic Artemisinin Development Deal.....II-91
AstraZeneca Files sNDA for Depressive Disorder Drug, Seroquel XR™.....II-91
1$100
   Forest, Mylan Amend Bystolic Agreement.....II-92
Fujifilm to Acquire Stake in Toyama Chemicals.....II-92
Graceway Takes Over Estrasorb.....II-92
1$100
   Ranbaxy Announces De-Merger of New-Drug Discovery Research Unit.....II-93
AstraZeneca Inks Deal with Nomura Phase4 Ventures to Form Albireo.....II-93
Cellegy to Merge with Adamis Pharmaceuticals.....II-93
Mylan Reaches Accord with Novartis for Femara®’s Generic Product.....II-93
1$100
   Dyax Signs Licensing and Development Agreements with Sanofi-aventis.....II-94
AstraZeneca Files for EU Approval of Seroquel XR™.....II-94
MedImmune Files Biologics License Application for motavizumab to FDA.....II-94
Farmavita, Belupo Sign Contract for Strategic Merger.....II-94
1$100
   Pfizer Japan Secures Production and Marketing Approval for Champix®.....II-95
Eisai Enters into License Agreement with Abbott.....II-95
1$100
   Eisai Takes Over MGI Pharma.....II-96
KV Pharmaceutical to Acquire Rights for Gestiva™ from Hologic.....II-96
Forest and Novexel Enter into Licensing Agreement.....II-96
1$100
   Dr. Reddy’s Enters Settlement Agreement with Novartis for Exelon®.....II-97
Taisho and Pfizer Sign Agreement for TS-032.....II-97
Crucell Enters into Agreement with Sanofi Pasteur.....II-97
1$100
   EMEA Approves Second Biogeneric EPO, Retacrit.....II-98
Endo Pharmaceuticals Licenses AZ-003 from Alexza.....II-98
Schering-Plough and Centocor Modify Existing Distribution Agreement.....II-98
1$100
   GSK and Santaris Pharma Collaborate in RNA Antagonists Research.....II-99
GSK Acquires Reliant Pharmaceuticals.....II-99
1$100
   Eisai and Minophagen Ink In-Licensing Agreement for Liver Disease/ Allergic Disease
  Agents.....II-100
Bristol-Myers, Gilead Extend Agreement to Commercialize ATRIPLA® in Europe.....II-100
1$100
   GSK and OncoMed Team Up for Antibody Therapeutics for Cancer Stem Cell
  Research.....II-101
GSK Allies with Galapagos for Antiviral and Antibacterial Development.....II-101
1$100
   Eisai and BioArctic Ink Licensing Deal for BAN2401.....II-102
Biogen and Neurimmune Join Hands to Develop Drugs for Alzheimer's Disease.....II-102
1$100
   Sanofi-aventis Institutes GDC, Pharmaceutical Development Center in India.....II-103
AstraZeneca Obtains Pediatric Exclusivity for ARIMIDEX® from FDA.....II-103
Covance to Build High-Tech Drug Development Facility.....II-103
1$100
   Schering-Plough Takes Over Organon BioSciences.....II-104
Takeda Launches Takeda San Francisco for Therapeutic Antibody Research.....II-104
GSK to Disinvest Lotronex®.....II-104
1$100
   Gilead and LGLS Enter Global License Deal for Fibrotic Diseases Therapy.....II-105
Watson Acquires Andrx.....II-105
1$100
   EPFL and Merck Serono Enter into Agreement.....II-106
Acura and King R&D Sign Licensing Agreement for Opioid Analgesic Products.....II-106
1$100
   Eli Lilly Inks License Agreement with Glenmark Pharmaceuticals.....II-107
Wockhardt Takes Over Morton Grove Pharmaceuticals.....II-107
1$100
   GSK Enters into Collaboration with Tolerx for Development of Novel Therapies.....II-108
Chugai Pharmaceuticals Obtains Approval for Tarceva in Japan.....II-108
Eli Lilly Announces Strategic Alliance with MacroGenics.....II-108
1$100
   BMS, ImClone, Merck Serono Sign Erbitux® Agreement.....II-1091$100
   Wockhardt to Market Gnosis’ SAMe in India.....II-110
Alpharma Grants US License for Ketoprofen in Transfersome® Gel to IDEA.....II-110
Forest and Daiichi Sankyo Sign Contract to Co-Promote AZOR™.....II-110
Synta and GSK Sign Oncology Molecule Development Collaboration.....II-110
1$100
   Cyclacel to Take Over ALIGN Pharmaceuticals and ALIGN Holdings.....II-111
GSK Inks Antiviral and Antibacterial Drug Development Deal with Anacor.....II-111
1$100
   AMRI Enters into Research Collaboration with Cystic Fibrosis Foundation.....II-112
Mylan Takes over Merck Generics.....II-112
Kissei and Eisai Ink Licensing Deal for Glufast® Tablets.....II-112
1$100
   AMRI Inaugurates New Research Unit in Hyderabad.....II-113
Eisai Inks Co-Promotion Deal with Salix for COLAZAL® Capsules.....II-113
Kowa and Teva to Establish Joint Venture Generic Drug Firm in Japan.....II-113
1$100
   Nisshin Seifun Pulls Out of Joint Venture Nisshin Kyorin Pharmaceutical.....II-114
Chugai and Teijin Sign Agreement for Co-Development of Anti-Diabetic Drug.....II-114
MedImmune Inks Licensing Agreement with Novartis over Reverse Genetic
  Technology.....II-114
1$100
   EUSA Acquires Assets of Innocoll.....II-115
Noven Enters Supply and License Agreements with P&G Pharmaceuticals.....II-115
1$100
   Parion and Gilead Ink Deal to Develop Drug Candidates for Pulmonary Disease.....II-116
Noven Pharmaceuticals Acquires JDS Pharmaceuticals.....II-116
1$100
   HHS Places an Order with GSK for Bulk H5N1 Antigen.....II-117
Synthon Completes Laboratorios Rider Acquisition.....II-117
1$100
   Targacept Forges Partnership with GSK.....II-118
Dong Wha Signs Alliance with P&G Pharma to Develop Treatment Molecules for
  Osteoporosis.....II-118
Barr and Gedeon Richter Sign Pact over Generic Version of LAMISIL®.....II-118
1$100
   Santarus and Victory Pharma Enter Into Co-Promotion Agreement.....II-119
AMRI Enters into Collaboration for Research with Achaogen.....II-119
1$100
   SCI Collaborates with High Q Foundation for Research on Huntington’s Disease.....II-120
MonoSol Rx Signs License Agreement with Strativa Pharmaceuticals.....II-120
Eli Lilly to Launch Public-Private Partnership for Drug Research in
  Tuberculosis.....II-120
1$100
   Merck Serono and Bristol-Myers Squibb Ink Latin American Distribution Deal.....II-121
Strides Arcolab to Take Over Bio-Fermentation Facility in Italy.....II-121
Amgen to Take Over Alantos Pharmaceuticals.....II-121
1$100
   GlaxoSmithKline Establishes R&D Center in China.....II-122
Wockhardt Acquires Negma Laboratories.....II-122
Eisai Inks Exclusive Agreement with Solstice over NeuroBloc®.....II-122
1$100
   Ranbaxy to Acquire Be-Tabs Pharmaceuticals.....II-123
Pfizer Obtains Health Canada Approval for LIPITOR in Reducing Myocardial
  Infarction.....II-123
1$100
   GSK Allies with Wellcome to Develop Antibacterials for Hospital-Contracted
  Infections.....II-124
Bristol-Myers and Pfizer Ink Development and Commercialization Agreements.....II-124
1$100
   Cytos Biotechnology Grants Novartis with Global License for NicQb.....II-125
Swiss Federal Register Adds ACOMPLIA® to Reimbursement List.....II-125
1$100
   Wockhardt to Introduce Syrio Pharma’s B-Lift Product Range in India.....II-126
Eisai Acquires Morphotex.....II-126
Ranbaxy Obtains Approval for RAN™ Cefprozil Formulations in Canada.....II-126
1$100
   Roche Partners with Transgene to Focus on Therapeutic Vaccine Program.....II-127
Cardinal Health Divests Pharmaceutical Technologies and Services Segment to Blackstone
  Group.....II-127
1$100
   Roche to Acquire BioVeris Corporation.....II-128
Eli Lilly Acquires Hypnion.....II-128
Roche Takes Over THP, Broadens Antibody Research Facility.....II-128
1$100
   Oxford BioMedica Enters into Development Deal with Sanofi-Aventis for
  TroVax®.....II-129
Iroko Pharmaceuticals Acquires Rights to Indocin® and Aldomet® Products.....II-129
Asahi Kasei Inks Licensing Agreement with Eisai Korea over Vasodilator Eril®.....II-129
1$100
   Merck Obtains EU Approval for JANUVIA™ Type 2 Diabetes Drug.....II-130
Wockhardt Obtains FDA Approval for a Painkiller in the US.....II-130
1$100
   Ortho-McNeil Obtains Pediatric Extension for LEVAQUIN®.....II-131
GlaxoSmithKline Obtains FDA Approval for Tykerb®.....II-131
Terapia Ranbaxy Secures Marketing Approvals for 20 New Products.....II-131
Shionogi to Develop and Market BioCryst's peramivir in Japan.....II-131
1$100
   Abbott and Eisai Amend Co-Promotion Agreement over HUMIRA® in Korea and
  Taiwan.....II-132
Salix Acquires US Rights to Merck’s Two Oral Suspension Products.....II-132
1$100
   Takeda Expands Collaboration with XOMA in Potential Therapeutic Antibody
  Programs.....II-133
GSK Commences Phase III Clinical Trials of Tykerb®, a Post-Operative
  Lapatinib.....II-133
1$100
   Roche Grants Glaxo with Exclusive Licensing Rights to its ‘Orlistat’ Drug.....II-134
GSK and HGS Commence Phase III Trials of LymphoStat-B® in SLE.....II-134
GSK and Fabre-Kramer Ink Global Deal for Gepirone ER.....II-134
1$100
   Ranbaxy Signs Agreement with Zenotech for Biosimilars’ Global Launch.....II-135
Ranbaxy Inks Long-Term R&D Deal with GSK.....II-135
1$100
   Amgen Inks Three-year Aranesp Supply Agreement with Fresenius.....II-136
AstraZeneca to Take Over Arrow Therapeutics.....II-136
Eli Lilly Acquires ICOS Corporation.....II-136
Pfizer Plans to Takeover BioRexis.....II-136
1$100
   Solvay Inks Licensing Deal with Jazz Pharmaceuticals for LUVOX®.....II-137
Eisai’s ‘Pariet®, 10mg Tablets’ Receive Clearance for New Indication in
  Japan.....II-137
Eisai Receives EC Approval for Inovelon®.....II-137
Pfizer Receives Marketing Authorization for Sutent® in European Union.....II-137
1$100
   GlaxoSmithKline Obtains Approval to Market Wellbutrin XR® in the Netherlands.....II-138
Forest Laboratories Acquires US Biopharmaceutical Company, Cerexa.....II-138
1$100
   Mylan Laboratories Acquires 51.5% in Matrix.....II-139
DUSA Enters into an Agreement with Daewoong Pharmaceutical.....II-139
Penwest and Endo Amend Existing Contract on Opana® ER Collaboration.....II-139
1$100
   Eli Lilly Licenses Glucokinase Activator Program from OSI Pharmaceuticals.....II-140
Graceway Pharmaceuticals Acquires 3M Pharmaceuticals Business.....II-140
Ranbaxy Obtains FDA Approval for Atenolol Tablets.....II-140
1$100
   Gilead Sciences Acquires Myogen.....II-141
Gilead Sciences Acquires Raylo Chemicals.....II-141
1$100
  9. FDA APPROVALS FOR 2009, 2008 AND 2007.....II-1422 $200  
   FDA Approvals for 2009, 2008 AND 2007.....II-142
2$200
  10. A REVIEW OF SELECT PRODUCT INTRODUCTIONS IN THE PHARMA INDUSTRY.....II-14423 $1200  
   Amgen Receives Approval for Nplate(R) .....II-144
Takeda Wins FDA Marketing Approval for ULORIC .....II-144
Novartis and MMV Launch Coartem® Dispersible.....II-144
Ipsen and Medicis Receives FDA Approval for Dysport .....II-144
1$100
   Centocor Receives FDA Approval for Simponi .....II-145
Wyeth Receives FDA Approval for PRISTIQ™ .....II-145
GSK Receives FDA Approval for Promacta® .....II-145
Cephalon Receives FDA Approval for TREANDA .....II-145
Adolor Receives FDA Approval For Entereg(R) .....II-145
1$100
   Lundbeck Introduces Xenazine* (Tetrabenazine) Tablets.....II-146
Eisai US Receives FDA Approval for Banzel™ (Rufinamide).....II-146
Progenics Receives FDA Approval for RELISTOR .....II-146
J&J Receives Approval for Anti-HIV Medication ‘Intelence’ .....II-146
Sandoz Launches Generic Fluoxetine Hydrochloride Capsules in US.....II-146
1$100
   Sandoz Introduces Eplerenone Tablets.....II-147
Wockhardt Introduces Midazolam Injection in the US.....II-147
Dr. Reddy’s Announces Launch of Generic Version of Imitrex® Tablets.....II-147
Arbor Pharmaceuticals Debuts NEOTIC™ for Middle- Ear Infections.....II-147
Promius Pharma Introduces EpiCeram® Emulsion.....II-147
1$100
   Sandoz Unveils Generic Variant of Imitrex® Injection.....II-148
Dr. Reddy’s Launches Redihaler™ and Combihale™.....II-148
Wyeth Launches Antihemophilic Factor, XYNTHA™.....II-148
Bayer Schering Releases YAZ®.....II-148
1$100
   Mylan Introduces Nisoldipine ER Tablets in US.....II-149
Ranbaxy Launches Generic Omeprazole in US.....II-149
Ranbaxy Unveils Generic Equivalent of Amlodipine Tablets.....II-149
Teva Unveils Generic Equivalent of Lamictal® Tablets.....II-149
1$100
   Eisai and Helsinn Healthcare Introduce ALOXI® Injection for Prevention of
  PONV.....II-150
Janssen and Patriot Unveil Authorized Generic Equivalent for Risperdal®.....II-150
Watson Releases Generic Equivalent of MARINOL®.....II-150
1$100
   Sandoz Introduces Generic Form of Altace®.....II-151
Abbott Introduces Aluvia® Tablet in South Africa.....II-151
Dr. Reddy’s Rolls-out Atocor-R.....II-151
Sandoz Unveils Generic Form of Maxipime®.....II-151
1$100
   Tibotec Therapeutics Introduces New 600mg Dosage Strength for PREZISTA.....II-152
Ranbaxy Pioneers Launch of New Bio-Generic Recombinant Osteoporosis
  Injection.....II-152
Sandoz Introduces Generic Variant of Antizol® Injection.....II-152
Sun Pharmaceuticals Introduces Injection of Amifostine.....II-152
1$100
   Sandoz Re-Launches Generic Form of Bactocill® Injection.....II-153
Sandoz Introduces Generic Form of Cipro® Injection.....II-153
Merck Serono Introduces Cyanokit® in Japanese Market.....II-153
Ranbaxy Launches INERSAN Tablets in India and Nepal.....II-153
Sandoz Launches Omnitrope™ Pen 5 with Liquid Cartridge.....II-153
1$100
   Endo Pharmaceuticals to Introduce OPANA® ER in Three Dosage Strengths.....II-154
Sandoz Releases Generic Form of Camptosar®.....II-154
Sun Pharmaceuticals Unveils Pantoprazole Sodium DR Tablets.....II-154
Dr. Reddy’s Introduces Supanac®.....II-154
1$100
   Watson Announces Launch of Clarithromycin 500mg Extended-Release Tablets.....II-155
GSK Announces FDA approval of Altabax™ .....II-155
Novartis’ Tekturna HCT® Receives FDA Approval .....II-155
GSK Receives FDA Approval for Tykerb® .....II-155
Pfizer Receives FDA Approval for Selzentr .....II-155
Ortho-McNeil Receives Approval for DORIBAX™ .....II-155
1$100
   Merck Receives Approval for Isentress® .....II-156
BMS Wins FDA Approval for IXEMPRA™ .....II-156
Novartis’ Tasigna® Receives FDA Approval .....II-156
Mylan Receives FDA Approval for Bystolic .....II-156
Roche’s Mircera Secures FDA Approval .....II-156
1$100
   Eisai Launches New Dose Formulations of Aricept® Tablets in Japan.....II-157
Chugai Launches Tarceva® Tablet in Japan.....II-157
Sandoz Introduces Generic Version of Elocon® Lotion.....II-157
Ranbaxy to Introduce Tamsulosin Hydrochloride Capsules in Canada.....II-157
Watson Unveils Tilia™ Fe.....II-157
1$100
   Ranbaxy Obtains Health Canada Approval for Ran®- Lisinopril Oral Tablets.....II-158
Sandoz Releases Generic Form of Delestrogen® Injections.....II-158
Sanofi and UCB Roll Out XYZAL® in US.....II-158
1$100
   Sandoz Expands Range of Generic Augmentin® Drugs.....II-159
Sandoz Releases Generic Variant of Biaxin® for Oral Suspension.....II-159
Sandoz Introduces Generic Form of Penlac® Topical Solution.....II-159
Teva Releases Famciclovir Tablets.....II-159
Ranbaxy Introduces Roliflo OD in India.....II-159
1$100
   Sandoz Introduces Generic Form of Toprol Xl® 50Mg Extended Release Tablet.....II-160
Dr. Reddy’s Introduces Glimy MP1 and Glimy MP2.....II-160
Sandoz Launches Approved Generic Equivalent of Lamisil®.....II-160
Ranbaxy Introduces Pravastatin Sodium 80mg Tablets in the US.....II-160
AstraZeneca Announces the Availability of Symbicort® pMDI.....II-160
1$100
   Chugai and Maruho Announce the Launch of Oxarol® Lotion.....II-161
Ajinomoto and Eisai Jointly Launch ‘Actonel® 17.5mg Tablets’.....II-161
Sandoz Introduces Approved Generic Form of Lotrel®.....II-161
1$100
   Dr. Reddy’s Launches UltravexTM.....II-162
Wockhardt Unveils Zolpidem Tablets in the US.....II-162
Dr. Reddy’s Introduces Reditux™.....II-162
Dr. Reddy’s Secures Approval for Launching Zolpidem Tartrate Tablets.....II-162
Cipla Introduces Virenza Inhalation Capsules in India.....II-162
1$100
   Ranbaxy Introduces Osovair in India.....II-163
GlaxoSmithKline Introduces Coreg CR™.....II-163
Chugai Announces the Launch of Antiviral Agent, Copegus® Tablet.....II-163
Ranbaxy Unveils Generic Atorvastatin in Denmark.....II-163
1$100
   Barr Unveils Generic ‘PROSCAR®’ Tablets.....II-164
Ranbaxy Introduces Niftran 100mg Capsules and Eligard 22.5mg and 45mg.....II-164
Barr Releases METAGLIP™ Tablets.....II-164
1$100
   SkinMedica Rolls Out Single-Dosage NeoBenz® Micro SD for Treating Acne.....II-165
Teva Rolls Out Generic Equivalent of Wellbutrin XI® Tablets.....II-165
Takeda Launches Takepron ® I.V for Injection 30mg.....II-165
1$100
   Takeda Launches duetact™ Combination Drug in USA.....II-166
Teijin Pharma Launches Bonalon® Tablet for Treating Osteoporosis.....II-166
1$100
  11. FOCUS ON SELECT GLOBAL PLAYERS.....II-16715 $950  
   Abbott Laboratories (USA).....II-167
Allergan, Inc. (USA).....II-167
1$100
   Amgen, Inc. (USA).....II-1681$100
   AstraZeneca (UK).....II-1691$100
   Bayer AG (Germany).....II-170
Bristol-Myers Squibb (USA).....II-170
Boehringer Ingelheim Group (Germany).....II-170
1$100
   Dr. Reddy's Laboratories Ltd. (India).....II-1711$100
   Eli Lilly and Company (USA).....II-172
F. Hoffmann-La Roche Ltd. (Switzerland).....II-172
1$100
   Genentech, Inc. (USA).....II-173
GlaxoSmithKline Plc (UK).....II-173
1$100
   Johnson & Johnson, Inc. (USA).....II-174
Merck & Co. Inc. (USA).....II-174
1$100
   Merck Serono International S.A. (Switzerland).....II-175
Mylan, Inc. (USA).....II-175
1$100
   Novartis AG (Switzerland).....II-1761$100
   Pfizer, Inc. (USA).....II-177
Ranbaxy Laboratories Limited (India).....II-177
1$100
   Sanofi-Aventis SA (France).....II-178
Sanofi Pasteur (France).....II-178
1$100
   Takeda Pharmaceutical Company Limited (Japan).....II-179
Teva Pharmaceutical Industries Ltd. (Israel).....II-179
1$100
   Watson Pharmaceuticals, Inc. (USA).....II-1801$100
   Wyeth (USA).....II-181
1$100
  12. GLOBAL MARKET PERSPECTIVE.....II-182   
   Table 25: World Recent Past, Current & Future Analysis for Prescription Drugs Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-1821$300
   Table 26: World Historic Review for Prescription Drugs Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....II-1831$300
   Table 27: World 15-year Perspective for Prescription Drugs Market by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-1841$300
   Table 28: World Recent Past, Current & Future Analysis for Prescription Drugs Market by Therapeutic Class – Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-1851$300
   Table 29: World Historic Review for Prescription Drugs Market by Therapeutic Class – Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....II-1861$300
   Table 30: World 15-year Perspective for Prescription Pharmaceuticals Market by Therapeutic Class– Percentage Breakdown of Dollar Sales for Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-1871$300
III. MARKET160$1950
  1. THE UNITED STATES.....III-174 $1825  
   A. Market Analysis.....III-1
Generics in the US.....III-1
Biologics Post Highest Growth.....III-1
1$75
   Leading Prescription Drugs in the US.....III-2
Table 31: Leading Prescription Drugs in the US by Value Sales (2008) in US$ Billion - Lipitor, Nexium, Plavix, Advair Diskus, Seroquel, Singulair, Enbrel, Neulasta, Actos and Epogen (includes corresponding Graph/Chart).....III-2
Leading Therapeutic Classes in the US.....III-2
1$150
   Table 32: US Leading Therapeutic Classes by Revenue (2006-2008): Revenues for Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorders, Anti-Depressants, Angiotensin II Antagonists, Anteneo Monoclonal Antibodies, Erythropoietins, Anti-Arthritics and Oral Antiplatelets (in US$ Billion) (includes corresponding Graph/Chart).....III-31$150
   Table 33: US Leading Therapeutic Classes by Dispensed Prescriptions (2006-2008): Percentage Share Breakdown for Lipid Regulators, Codiene & Combinations, Anti-Depressants, Ace Inhibitors, Beta Blockers, Proton Pump Inhibitors, Seizure Disorders, Synthetic Thyroid Hormones, Calcium Blockers, Benzodiazepines, and Others (includes corresponding Graph/Chart).....III-41$150
   Leading Players.....III-5
Table 34: Leading Companies in the US Pharmaceutical Market (2006-2008): Percentage Breakdown of Value Sales for Pfizer, GlaxoSmithKline, Merck & Co., Johnson & Johnson, AstraZeneca, Amgen, Novartis, Hoffman-La Roche, Sanofi-Aventis, Eli Lilly and Others (includes corresponding Graph/Chart).....III-5
1$150
   Table 35: US Pharmaceutical Market (2006-2008): Percentage Breakdown of Dispensed Prescriptions for Teva Pharmaceuticals, Mylan Laboratories, Novartis, Watson Pharma, Pfizer, Barr Laboratories, Merck & Co., Mallinckrodt, Apotex, Qualitest, and Others (includes corresponding Graph/Chart).....III-6
Prescription Drug Spending.....III-6
1$150
   Table 36: Healthcare Spending in the US by Sector (2006) (includes corresponding Graph/Chart).....III-71$150
   Increasing Share of Government in Prescription Drug Spending.....III-8
Table 37: US Prescription Pharmaceutical Industry (2005 and 2006): Percentage Breakdown of Prescription Pharmaceutical Spending by Source for Private Insurance, Medicare, Medicaid, Out-of-Pocket and Other Public Spending (includes corresponding Graph/Chart).....III-8
Medicare Part D.....III-8
1$150
   Drug Price Regulations in the US.....III-9
Pharmaceutical Marketing – A High Investment Area in the US.....III-9
1$75
   Table 38: Pharmaceutical Promotional Spending in the US by Type (2006-2008): Professionals-Directed Promotions and Consumer-Directed Promotions (in US$ Billion) (includes corresponding Graph/Chart).....III-10
Major Distribution Channels.....III-10
1$150
   Table 39: Major Prescription Drugs’ Distribution Channels in the US by Dispensed Prescriptions (2006-2008): Percentage Share Breakdown for Chain Stores, Independent Stores, Food Stores, Long-term Care, and Mail Order (includes corresponding Graph/Chart).....III-11

Table 40: Major Prescription Drugs’ Distribution Channels in the US by Value Sakes (2006-2008): Percentage Breakdown for Distribution Channel for Chain Stores, Mail Order, Independent Stores, Clinics, Non-government Hospitals, Food Stores and Other Channels (includes corresponding Graph/Chart).....III-11
1$150
   Fewer Product Launches.....III-12
Generic Penetration and PBMs Moderate Prescription Drug Price Growth.....III-12
Co-payment Differentials to Increase Generic Substitution.....III-12
High Prescription Drug Costs Drive Drug Re- Importation.....III-12
Direct-to-Consumer Advertising.....III-12
1$75
   The 2006 Revision of Package Insert Format.....III-13
Other Initiatives.....III-13
Role of PBMs in the Pharmaceutical Supply Chain.....III-13
1$75
   Prescription Drug Pricing in US.....III-141$75
   Role of Mail-Order Pharmacies in Cost Containment.....III-15
Product Launches.....III-15
15$725
   Strategic Corporate Developments.....III-3033$975
   Select Key Players.....III-638$400
   B. Market Analytics.....III-71
Table 41: US Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-71

Table 42: US Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-71
1$150
   Table 43: US Recent Past, Current & Future Analysis for Prescription Pharmaceuticals by Therapeutic Class – Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, Others, Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-721$150
   Table 44: US Historic Review for Prescription Pharmaceuticals by Therapeutic Class – Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, Others, Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-731$150
   Table 45: US 15-Year Perspective for Prescription Pharmaceuticals by Therapeutic Class – Percentage Breakdown of Dollar Sales for Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, and Others for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....III-74
1$150
  2. CANADA.....III-758 $725  
   A. Market Analysis.....III-75
Current and Future Analysis.....III-75
Leading Drugs.....III-75
Table 46: Leading Prescription Drugs in Canada in Terms of Number of Dispensed Prescriptions (2006 and 2007) in Million Scripts: Lipitor, Synthroid, Norvasc, Asaphen, Pantoloc, Crestor, Altace, Ratio-Salbutamol Hfa, Novo-Venlafaxine XR and Apo- Furosemide (includes corresponding Graph/Chart).....III-75
1$150
   Major Therapeutic Classes.....III-76
Table 47: Leading Therapeutic Classes in Canada in terms of Dispensed Prescription (2006 and 2007): Percentage Breakdown of Cardiovascular, Antipsychotics, Gastrointestinal/Genitourinary, Lipid Regulators, Hormones, Systemic Anti-infective, Analgesics, Diabetes Therapy, Diuretics, Neurological Disorders and Others (includes corresponding Graph/Chart).....III-76
1$150
   Prescription Drugs Spending on the Rise.....III-77
Private Sector Insurance Continues to Gain Popularity.....III-77
Canadian Prescription Drugs Market- A Comparison with the US.....III-77
Generic Sales to Outpace Branded Drugs Sales.....III-77
Generics Market in Canada.....III-77
Generics to Offer Potential Cost Savings.....III-77
1$75
   New Patented Drugs- Adding Costs but Little Value.....III-78
Two-level Drug Approval Process in Canada.....III-78
Policy Differences Affect Generic Substitution Among Provinces.....III-78
Applied and Other Research Take Major Chunk of R&D Investments in Canada.....III-78
1$75
   Table 48: Investments in Research & Development in Canada (1998, 2001, 2004 and 2007): Percentage Breakdown by Research Type- Applied Research, Basic Research and Other Research Areas (includes corresponding Graph/Chart).....III-79
Product Launches.....III-79
2$300
   Strategic Corporate Developments.....III-811$75
   B. Market Analytics.....III-82
Table 49: Canadian Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-82

Table 50: Canadian Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-82
1$150
  3. JAPAN.....III-8313 $675  
   A. Market Analysis.....III-83
Current and Future Analysis.....III-83
Generics Promotion in Japan.....III-83
Ageing Population – A Prime Target.....III-83
1$75
   Competitive Landscape.....III-84
Table 51: Leading Pharmaceutical Companies in Japan (2008): Percentage Breakdown of Revenues for Takeda Pharmaceuticals, Astellas Seiyaku, Dai-ichi Sankyo, Mitsubishi Tanabe, Chugai Seiyaku, Pfizer, Novartis, Eisai, GlaxoSmithKline and Otsuka Seiyaku (includes corresponding Graph/Chart).....III-84
1$150
   Table 52: Leading Prescription Drugs in Japan (2008): Value Sales in US$ Million for Blopress, Diovan, Norvasc, Lipitor, Aricept, Epogin, Takepron, Leuplin, Micardis and Amlodin (includes corresponding Graph/Chart).....III-85
Cancer Drugs to Witness Robust Growth.....III-85
Biennial Price Reduction to Impact Markets of Key Therapeutic Classes.....III-85
1$150
   Product Launches.....III-862$150
   Strategic Corporate Developments.....III-886$250
   Select Key Players.....III-941$75
   B. Market Analytics.....III-95
Table 53: Japanese Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-95

Table 54: Japanese Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-95
1$150
  4. EUROPE.....III-9634 $1475  
   A. Market Analysis.....III-96
Current and Future Analysis.....III-96
Pharmaceutical Spending on the Rise.....III-96
Mounting Healthcare Bills Boost Generic Drugs Consumption.....III-96
1$75
   Biogenerics Foray into Europe.....III-97
SNRIs Likely to Replace SSRIs.....III-97
Research and Development.....III-97
Table 55: European Investments in Pharma Research & Development: 2005-2007 (includes corresponding Graph/Chart).....III-97
1$150
   Europe - The Research and Production Hub for Vaccines Worldwide.....III-98
Parallel Trade in Europe.....III-98
New Rules to Offer Respite to Parallel Traders.....III-98
Manufacturers Seek Greater Control Over Supply Chain.....III-98
1$75
   Pharmaceutical Industry Overview In Select Countries.....III-99
France.....III-99
Germany.....III-99
Generics.....III-99
1$75
   Exports.....III-100
Production.....III-100
Prices.....III-100
New Molecular Entities.....III-100
R&D Investments.....III-100
Parallel trade.....III-100
1$75
   Genetically Manufactured Drugs.....III-101
Table 56: German Genetically Manufactured Pharmaceuticals (2007): Percentage Breakdown of Sales by Type - Vaccines, Insulins, Interferons, Monoclonal Antibodies, Erythropoietin, and Others (includes corresponding Graph/Chart).....III-101
United Kingdom.....III-101
Spain.....III-101
1$150
   Cost Containment Efforts.....III-102
Increased Promotion for Generics.....III-102
Re-launch of Reference Price System.....III-102
Distribution.....III-102
1$75
   Italy.....III-103
Generics Gain Traction.....III-103
Sweden.....III-103
Greece.....III-103
Unique Pricing Model for Drugs.....III-103
1$75
   Product Launches.....III-1042$150
   Strategic Corporate Developments.....III-10617$800
   Select Key Players.....III-1235$375
   B. Market Analytics.....III-128
Table 57: European Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-128
1$150
   Table 58: European Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-129
1$150
  5. ASIA-PACIFIC.....III-13026 $1450  
   A. Market Analysis.....III-130
Current and Future Analysis.....III-130
Overview of Pharmaceutical Industries in Select Countries.....III-130
India.....III-130
Competitive Advantage.....III-130
1$75
   Number of FDA Approved Plants in India Vis-à-Vis Other Countries.....III-131
Increasing Disposable Income Driving Consumption of Drugs.....III-131
Generics to Surge Growth in Exports.....III-131
Manufacturers Continue to Target Developed Markets.....III-131
1$75
   India to Emerge as an Important Pharmaceutical Manufacturing Center.....III-132
Threat from Other Asian Countries.....III-132
India to Emerge as a Major Hub for Biogenerics.....III-132
Acute Therapy Class Leads the Market.....III-132
1$75
   Table 59: Leading Therapeutic Categories in the Indian Pharmaceutical Industry- Percentage Share Breakdown of Value Sales for Anti-infectives, Gastrointestinal, Cardiovascular, Respiratory, Minerals and Vitamins, Analgesics, Women’s Health, Central Nervous System, Dermatology, and Others (includes corresponding Graph/Chart).....III-133
Increase in Private Healthcare Services.....III-133
China.....III-133
1$150
   Chinese Pharma Industry Remains Immune to Global Crisis, for Now.....III-134
Issues and Trends.....III-134
1$75
   Pharmaceutical Firms to Play Pivotal Role in Transforming Healthcare
  System.....III-135
Brand Name Drugs to Exhibit Fastest Growth, While Generics Continue to
  Lead.....III-135
Generics in China.....III-135
1$75
   Traditional Medicines – Substantial Share.....III-136
Table 60: Leading Medicine Types in China (2005): Percentage share for Allopathic Medicines, Traditional Chinese Medicines (TCM), and Other Drugs (includes corresponding Graph/Chart).....III-136
1$150
   Underserved Markets Prompt Government to Foster Development.....III-137
Domestic EPO Market Booming, Domestic Players Continue their Domination.....III-137
Chinese Antipsychotics Market to Witness Substantial Growth.....III-137
1$75
   Antidepressant Drugs to Exhibit Robust Sales.....III-138
Indonesia.....III-138
Market Features.....III-138
Government-Enforced Pricing Control Over Essential Drugs.....III-138
1$75
   Distribution.....III-139
Korea.....III-139
Patent Expiries of Leading Drugs in South Korea: 2008 and 2009.....III-139
1$75
   Malaysia.....III-140
Foreign Investments on the Rise.....III-140
Domestic Market.....III-140
1$75
   Australia.....III-141
Pharmaceutical Benefits Scheme.....III-141
1$75
   Government’s Industry Development Programs.....III-142
Outlook.....III-142
1$75
   Product Launches.....III-1433$225
   Strategic Corporate Developments.....III-1467$375
   Select Key Players.....III-1532$150
   B. Market Analytics.....III-155
Table 61: Asia-Pacific Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-155

Table 62: Asia-Pacific Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-155
1$150
  6. LATIN AMERICA.....III-1562 $150  
   A. Market Analysis.....III-156
Current and Future Analysis.....III-156
Strategic Corporate Developments.....III-156
1$75
   B. Market Analytics.....III-157
Table 63: Latin American Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-157

Table 64: Latin American Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-157
1$150
  7. REST OF WORLD.....III-1583 $225  
   A. Market Analysis.....III-158
Current and Future Analysis.....III-158
Product Launches.....III-158
Strategic Corporate Developments.....III-158
2$150
   B. Market Analytics.....III-160
Table 65: Rest of World Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-160

Table 66: Rest of World Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-160
1$150
IV. COMPETITIVE LANDSCAPE 1426$995
  
Total Companies Profiled: 292 (including Divisions/Subsidiaries - 360)

Region/Country                 Players


The United States                246
Canada                             4
Japan                             27
Europe                            57
     France                        4
     Germany                       9
     The United Kingdom           11
     Italy                         4
     Rest of Europe               29
Asia-Pacific (Excluding Japan)    22
Latin America                      1
Africa                             3
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.